TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Wise App Trial for Improving Health Outcomes in People Living With HIV
Brief Summary: The overall goal of this study is to design a user-centered design app linked to a smart pill box for people living with HIV (PLWH) and evaluate its effects in a randomized controlled trial. The proposed trial is scientifically significant in representing a principled and systematic effort to test the efficacy of a smartphone intervention linked to a smart pill box for antiretroviral (ART) adherence in PLWH in the United States (US). Guided by a strong theoretical framework building on earlier user-centered design work and integrating a real-time monitoring device, this work has the potential to improve ART adherence in PLWH and have a sustainable public health impact.


Options:
A: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Behavioral: Wise app with fitness reminders | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Wise app with medication adherence reminders | Intervention Type: BEHAVIORAL; Name: Wise app with medication adherence reminders; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Wise app with fitness reminders; Assigned to Arm(s): Control
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text message; Type: ACTIVE_COMPARATOR; Interventions: Other: SMS reminder message | Arm Label: Text message and voice call; Type: ACTIVE_COMPARATOR; Interventions: Other: Voice call + SMS message | Intervention Type: OTHER; Name: SMS reminder message; Assigned to Arm(s): Text message | Intervention Type: OTHER; Name: Voice call + SMS message; Assigned to Arm(s): Text message and voice call
C: Arm Label: Text-Based Adherence Game; Type: EXPERIMENTAL; Interventions: Behavioral: Text-Based Adherence Game, Behavioral: Standard of Care (SOC) | Arm Label: Standard of Care (SOC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care (SOC) | Intervention Type: BEHAVIORAL; Name: Text-Based Adherence Game; Assigned to Arm(s): Text-Based Adherence Game | Intervention Type: BEHAVIORAL; Name: Standard of Care (SOC); Assigned to Arm(s): Standard of Care (SOC), Text-Based Adherence Game
D: Arm Label: Telephone reminder; Type: EXPERIMENTAL; Interventions: Other: Telephone reminder | Arm Label: Text Message reminder; Type: EXPERIMENTAL; Interventions: Other: Text Message reminder | Arm Label: Control: Telephone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control: Text Message; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone reminder; Assigned to Arm(s): Telephone reminder | Intervention Type: OTHER; Name: Text Message reminder; Assigned to Arm(s): Text Message reminder

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents
Brief Summary: The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).


Options:
A: Arm Label: OMS721; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721
B: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ravulizumab, Biological: Eculizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Eculizumab, Ravulizumab | Intervention Type: BIOLOGICAL; Name: Eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma
Brief Summary: Cluster of differentiation antigen 19(CD19) specifically presents in B lymphocyte cell lines steadily,while not in most normal tissue,including pluripotent hematopoietic stem cells.Cluster of differentiation antigen 20(CD20) presents in 90% of B-cell lymphomas.CD19 antigen is a well-established target for B-cell lymphomas treatment as well as CD20 antigen.Both CD19-targeting CAR T Cells and CD20-targeting CAR T Cells can be used as adoptive cellular immunotherapies for B-cell lymphomas.Though two kinds of single target treatments were proved can induce recession of B-cell lymphomas, the risk of cancer cells to escape and tumor recurrence are still existed. There are no report about combination transfer of two kinds of single target treatments.This research aimed emphasis on safety and therapeutic efficacy evaluation,as well as if combination transfer can decrease recurrence rate.


Options:
A: Arm Label: ACTR707 in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR707, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR707; Assigned to Arm(s): ACTR707 in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR707 in combination with rituximab
B: Arm Label: anti-CD19 and anti-CD20 dual specific CAR-T Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells | Intervention Type: BIOLOGICAL; Name: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells; Assigned to Arm(s): anti-CD19 and anti-CD20 dual specific CAR-T Cells
C: Arm Label: CAR-CD19 T cells; Type: EXPERIMENTAL; Interventions: Genetic: CAR-CD19 T cells, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: GENETIC; Name: CAR-CD19 T cells; Assigned to Arm(s): CAR-CD19 T cells | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): CAR-CD19 T cells | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): CAR-CD19 T cells
D: Arm Label: Mixed CD19/CD20 CAR-T Transfer; Type: EXPERIMENTAL; Interventions: Biological: Mixed CD19/CD20 CAR-T Transfer | Intervention Type: BIOLOGICAL; Name: Mixed CD19/CD20 CAR-T Transfer; Assigned to Arm(s): Mixed CD19/CD20 CAR-T Transfer

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT: Effect of Coaching on Mid-Career Physician Well-Being, Job Satisfaction, and Fulfillment
Brief Summary: The study will assess the effect of individualized professional coaching for mid-career family medicine and general internal medicine physicians on burnout, job satisfaction, and professional fulfillment.


Options:
A: Arm Label: CORE condition; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Healthy lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy lifestyle | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): CORE condition | Intervention Type: BEHAVIORAL; Name: Healthy lifestyle; Assigned to Arm(s): Healthy lifestyle
B: Arm Label: Mobile Video Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Stress management counseling | Arm Label: Offline Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management counseling | Arm Label: Selfcare; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress management counseling; Assigned to Arm(s): Mobile Video Counseling, Offline Counseling
C: Arm Label: Induction; Type: EXPERIMENTAL; Interventions: Other: Induction | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: OTHER; Name: Induction; Assigned to Arm(s): Induction | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Immediate Coaching Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Professional Coaching | Arm Label: Control/Delayed Coaching Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Professional Coaching | Intervention Type: BEHAVIORAL; Name: Professional Coaching; Assigned to Arm(s): Control/Delayed Coaching Intervention, Immediate Coaching Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT: Effect of Coaching on Mid-Career Physician Well-Being, Job Satisfaction, and Fulfillment
Brief Summary: The study will assess the effect of individualized professional coaching for mid-career family medicine and general internal medicine physicians on burnout, job satisfaction, and professional fulfillment.


Options:
A: Arm Label: Mental Training for Residents; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Stress Resilience Training (ESRT) | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Enhanced Stress Resilience Training (ESRT); Assigned to Arm(s): Mental Training for Residents | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
B: Arm Label: Immediate Coaching Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Professional Coaching | Arm Label: Control/Delayed Coaching Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Professional Coaching | Intervention Type: BEHAVIORAL; Name: Professional Coaching; Assigned to Arm(s): Control/Delayed Coaching Intervention, Immediate Coaching Intervention
C: Arm Label: Nurse led intervention group; Type: EXPERIMENTAL; Interventions: Other: Nurse led intervention group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nurse led intervention group; Assigned to Arm(s): Nurse led intervention group
D: Arm Label: Mindful Awareness Practices (MAPs); Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Awareness Practices (MAPs) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Awareness Practices (MAPs); Assigned to Arm(s): Mindful Awareness Practices (MAPs)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Lifestyle Interventions With Mindfulness-based Strategies in Type 2 Diabetes
Brief Summary: Type 2 diabetes mellitus (T2DM) is the most expensive chronic disease in the U.S.

Lifestyle modification is central to T2DM management, but long-term adherence to dietary recommendations is difficult. A key challenge is the difficulty of coping with cravings for high carbohydrate or sugar-laden foods in an environment where these foods are tempting and widely available. One mechanism by which mindfulness may increase long-term dietary adherence is by better equipping individuals with skills to experience food cravings and difficult emotions without eating in response. Such approaches seek to strengthen abilities to be non-judgmentally aware of, tolerate, and respond skillfully to food cravings and difficult emotions without reacting impulsively or maladaptively. The investigators hypothesize that improved ability to manage food cravings and emotional eating is a key mechanism through which mindfulness-enhancements can improve dietary adherence. The study will test a mindfulness-based intervention (MBI) for improving dietary adherence. Although the particular diet employed is not the focus of this study, the study will use a diet with about 10% of calories from carbohydrate as: (1) it induces a low level of ketone production, which will be used as a biomarker for dietary adherence; (2) prior studies suggest it improves metabolic parameters in T2DM, including glycemic control.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Meditation | Arm Label: Group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Meditation; Assigned to Arm(s): Group 1, Group 2
B: Arm Label: Diet Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Carbohydrate-restricted diet | Arm Label: Diet Education + Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Carbohydrate-restricted diet, Behavioral: Mindfulness | Intervention Type: BEHAVIORAL; Name: Carbohydrate-restricted diet; Assigned to Arm(s): Diet Education, Diet Education + Mindfulness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Diet Education + Mindfulness
C: Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction; Assigned to Arm(s): N/A
D: Arm Label: Stress reduction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress reduction | Arm Label: Stress reduction with Health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress reduction with Health education | Intervention Type: BEHAVIORAL; Name: Stress reduction; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Stress reduction with Health education; Assigned to Arm(s): Stress reduction with Health education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Primary Minimal Change Nephropathy: a Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D
Brief Summary: Traditionally MCN is treated with a high dose of prednisolone, which induces remission in 60-90% of patients. Prednisolone treatment contains numerous side effects and the current dose is empiric. Given the lack of efficacy evidence and the risk associated with the currently accepted treatment regimen there is a need to characterize the outcome in MCN further, and to establish new, and potentially less toxic treatment regimens.

The aim is to examine if treatment with reduced dose of prednisolone in combination with activated vitamin D is as effective as standard high dose prednisolone in achieving remission and preventing relapse in MCN, and if reduced dose prednisolone is associated with fewer side effects compared to standard dose. Furthermore, the study will examine the influence of prednisolone metabolism on the efficacy and side effects of prednisolone in the treatment of MCN.


Options:
A: Arm Label: High dose prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: Alfacalcidol and low dose prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: Alfacalcidol | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Alfacalcidol and low dose prednisolone, High dose prednisolone | Intervention Type: DRUG; Name: Alfacalcidol; Assigned to Arm(s): Alfacalcidol and low dose prednisolone
B: Intervention Type: DRUG; Name: long term tapering of prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: standard prednisolone treatment; Assigned to Arm(s): N/A
C: Arm Label: B-Experimental; Type: EXPERIMENTAL; Interventions: Drug: acid mycophenolic (Myfortic) | Arm Label: A-Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A-Active Comparator | Intervention Type: DRUG; Name: acid mycophenolic (Myfortic); Assigned to Arm(s): B-Experimental
D: Arm Label: Intervention: Prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Intervention: Prednisolone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CareToy Observational Study: Early Identification of Infants at Risk of Cerebral Palsy
Brief Summary: This observational study aims to early identify, through a rigorous and standardized follow-up, infants at high risk for Cerebral Palsy. After the consent agreement firmed by the parents, infants born at term or preterm with ultrasonographic evidence of brain injury considered at risk for neurodevelopmental disorders will be strictly monitored during the first months of life performing a periodic neurological assessment (Prechtl's General Movement (GMA) and the Hammersmith Infant Neurological Examination) at term age and around 3 months of post term age. Moreover, to study more accurately the brain injury early identified by ultrasonographic brain exam, around 6 weeks of post-term age the enrolled infants will perform, as recommended in infants at risk, brain Magnetic Resonance (RM).

Thanks to the high predictability power of the combination of the clinical observation with the neuroimaging infants at high risk of CP will be early detect. Selected infants, considered at high risk for CP will have the opportunity to perform an home based and family centered early intervention later than 3 post term age.


Options:
A: Arm Label: Phase 1: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Phase 1: Facilitated infant care; Type: EXPERIMENTAL; Interventions: Behavioral: Family Nurture Intervention | Arm Label: Phase 2: Effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family Nurture Intervention | Intervention Type: BEHAVIORAL; Name: Family Nurture Intervention; Assigned to Arm(s): Phase 1: Facilitated infant care, Phase 2: Effectiveness
B: N/A
C: Arm Label: CareToy; Type: EXPERIMENTAL; Interventions: Device: CareToy | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: DEVICE; Name: CareToy; Assigned to Arm(s): CareToy | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
D: Arm Label: Early stimulation; Type: EXPERIMENTAL; Interventions: Other: Early stimulation | Arm Label: Conventional care; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional care | Intervention Type: OTHER; Name: Early stimulation; Assigned to Arm(s): Early stimulation | Intervention Type: OTHER; Name: Conventional care; Assigned to Arm(s): Conventional care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mifepristone and Misoprostol Versus Misoprostol Alone for Uterine Evacuation After Early Pregnancy Failure: a Randomized Double Blind Placebo-controlled Comparison (Triple M Trial)
Brief Summary: This study aims to compare whether a combination of two drugs (Mifepristone and misoprostol) are superior compared to using only one of these drugs (Misoprostol) as medical treatment for a miscarriage. Women in whom early pregnancy failure, 6-14 weeks postmenstrual, is ultrasonographically confirmed qualify for this study.

It is expected that the combination of Mifepristone and Misoprostol is more effective in reaching complete evacuation, and therefore can prevent more invasive treatment such as curettage.


Options:
A: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
B: Arm Label: Arm A : Operative hysteroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Hysteroscopy | Arm Label: Arm B : Aspirative curettage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Curettage | Intervention Type: PROCEDURE; Name: Hysteroscopy; Assigned to Arm(s): Arm A : Operative hysteroscopy | Intervention Type: PROCEDURE; Name: Curettage; Assigned to Arm(s): Arm B : Aspirative curettage
C: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mifepristone and Misoprostol Versus Misoprostol Alone for Uterine Evacuation After Early Pregnancy Failure: a Randomized Double Blind Placebo-controlled Comparison (Triple M Trial)
Brief Summary: This study aims to compare whether a combination of two drugs (Mifepristone and misoprostol) are superior compared to using only one of these drugs (Misoprostol) as medical treatment for a miscarriage. Women in whom early pregnancy failure, 6-14 weeks postmenstrual, is ultrasonographically confirmed qualify for this study.

It is expected that the combination of Mifepristone and Misoprostol is more effective in reaching complete evacuation, and therefore can prevent more invasive treatment such as curettage.


Options:
A: Intervention Type: DRUG; Name: 800 mcg misoprostol via oral or buccal administration; Assigned to Arm(s): N/A
B: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
C: Arm Label: misoprostol plus mifepristone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol, Drug: Mifepristone | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol, misoprostol plus mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): misoprostol plus mifepristone
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: B